Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Characteristics of JP-2266 in Healthy Subjects

Phase 1 Unknown 80 enrolled Jeil Pharmaceutical Co., Ltd.

RandomizedParallel-groupDouble-blindTreatment

Summary

Phase I Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Characteristics of JP-2266 after Oral Administration in Healthy Male Caucasian Subjects

Timeline

Start: 2020-11-24
Primary completion: 2022-08-31
Completion: 2022-08-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	JP-2266	Unknown	—	Oral

Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Characteristics of JP-2266 in Healthy Subjects

Summary

Timeline

Drugs

Indications